Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
04:47pm, Tuesday, 05'th Nov 2024
Sales of the company's top commercialized product didn't meet expectations.
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Transcript
03:14pm, Tuesday, 05'th Nov 2024
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Meredith Kaya - Senior Vice President of Investor Relations and Strategic
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say
10:36am, Tuesday, 05'th Nov 2024
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compa
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates
09:21am, Tuesday, 05'th Nov 2024
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
07:05am, Tuesday, 05'th Nov 2024
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2024 financial results and business highlights.
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
11:06am, Tuesday, 29'th Oct 2024
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
05:51am, Tuesday, 29'th Oct 2024
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT study were presented as an oral
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
02:56pm, Wednesday, 16'th Oct 2024
William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. APLS and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of two thera
Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years
09:15am, Wednesday, 09'th Oct 2024
24/7 Wall St. Insights Here are some candidates to be the best-performing growth stock over the next five years.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant da
Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)
05:31am, Friday, 04'th Oct 2024
Apellis Pharmaceuticals' Syfovre, despite initial safety concerns, shows strong revenue growth and is nearing profitability, making it a high-risk, high-reward investment. Syfovre's adjusted safety pr
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm
12:16pm, Thursday, 03'rd Oct 2024
NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
01:15pm, Tuesday, 01'st Oct 2024
Despite the CHMP's negative opinion on pegcetacoplan for GA in Europe, Apellis still has significant growth potential in the U.S. and other markets. The U.S. market remains crucial for Apellis, with S
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
07:00am, Wednesday, 25'th Sep 2024
WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on Wedn
